HOOKIPA to Participate in the JMP Securities Life Sciences Conference

Rhea-AI Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in investor meetings at the JMP Securities Life Sciences Conference on June 15-16, 2022, in New York City. The company focuses on developing immunotherapeutics based on its proprietary arenavirus platform, which aims to enhance T cell responses against serious diseases. HOOKIPA's pipeline includes therapies targeting HPV16+ cancers, prostate cancer, and KRAS-mutated cancers. Additionally, it seeks to develop functional cures for HBV and HIV in collaboration with Gilead.

NEW YORK and VIENNA, Austria, June 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in investor meetings at the JMP Securities Life Sciences Conference being held in New York City, June 15 - 16, 2022.

About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly-owned investigational arenaviral immunotherapeutics targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Media	Investors
Michael Szumera	Matt Beck
Executive Director - Communications	Executive Director - Investor Relations
michael.szumera@hookipapharma.com	matthew.beck@hookipapharma.com
+1 917 561 8905	+1 917 209 6886

FAQ

What is HOOKIPA Pharma's participation in the JMP Securities Life Sciences Conference?

HOOKIPA Pharma will participate in investor meetings at the JMP Securities Life Sciences Conference on June 15-16, 2022, in New York City.

What type of therapies does HOOKIPA Pharma develop?

HOOKIPA Pharma develops immunotherapeutics based on its proprietary arenavirus platform aimed at enhancing T cell responses against various cancers and serious diseases.

What are the main targets in HOOKIPA Pharma's pipeline?

HOOKIPA Pharma's pipeline targets include HPV16+ cancers, prostate cancer, KRAS-mutated cancers, and aims to develop cures for HBV and HIV in collaboration with Gilead.

When is the JMP Securities Life Sciences Conference taking place?

The JMP Securities Life Sciences Conference is happening on June 15-16, 2022.

What is the stock symbol for HOOKIPA Pharma?

The stock symbol for HOOKIPA Pharma is HOOK.